The Lung Cancer Prediction AI is designed to assist in the diagnosis of incidental pulmonary nodules, which can often be difficult to assess due to their indeterminate nature. It is common for patients to undergo multiple procedures over a prolonged period of time before a definite diagnosis is reached. This can result in delayed treatment for those with cancer and unnecessary aggressive procedures for those with benign conditions.
Studies have shown that the Lung Cancer Prediction AI can significantly increase the accuracy of malignancy assessments, with pulmonologists and radiologists showing improvements in both sensitivity and specificity at high and low risk ACCP guideline thresholds. It also helps to reduce variations between individual physicians, improving the diagnostic accuracy of every pulmonologist and radiologist and making them more consistent with each other.
In terms of clinical management, the use of the Lung Cancer Prediction AI has been shown to lead to more appropriate decisions for 22% of patients with malignant nodules. The product has been clinically validated in multi-center studies and published in leading medical journals by guidelines co-authors.